FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:532-533 July 30, 2009 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by The GISSI-AF Investigators PubMed Citation

To the Editor: Disertori et al. (April 16 issue)¹ describe the effects of valsartan on the recurrence of atrial fibrillation. The disappointing results of the trial may be explained by two important limitations. First, no data were provided concerning how long patients were known to have had either atrial fibrillation or underlying heart disease. We would expect that the extent of remodeling would become more severe and even irreversible in patients with a longer history of atrial fibrillation or underlying heart disease. In patients with a shorter history, however, remodeling processes are less advanced, providing more opportunities for blockade of . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.